Marvel franchise actor Evangeline Lilly shared that she’s been dealing with the effects of a traumatic brain injury after falling months ago in Hawaii. In a video posted to Instagram, Lilly told ...

This is read by an automated voice. Please report any issues or inconsistencies here. Evangeline Lilly says much of her brain is “functioning at a decreased capacity” after her traumatic brain injury ...

Eli Lilly has returned to Nimbus Therapeutics for another metabolic collaboration, this time focused on the red-hot R&D space of oral obesity therapies. The latest partnership will see Lilly pass ...

Evangeline Lilly says she has brain damage, months after fainting and hitting her head on a rock while at the beach. “It’s late on January 1st. The first day of 2026. And I’m entering into this new ...

Evangeline Lilly received the results of her brain scan after suffering a concussion. “It’s late on January 1, the first day of 2026, and I’m entering into this new year — the year of the horse — with ...

Boston biotech Nimbus Therapeutics is teaming up with Eli Lilly & Co. to develop a new oral obesity treatment in a deal worth up to $1.3 billion, the company announced Tuesday. It’s the latest move in ...

In 2026, new obesity pills will push the booming GLP-1 market into its next chapter. Pills may serve as a more convenient — and in certain cases cheaper — alternative to today's blockbuster injections ...

Eli Lilly LLY-2.12%decrease; red down pointing triangle is in advanced talks to acquire Ventyx Biosciences VTYX 0.79%increase; green up pointing triangle for around $1 billion, according to people ...

Novo Nordisk was the first company to introduce a GLP-1 shot. Eli Lilly's GLP-1 shot quickly became the industry leader after its introduction. Novo Nordisk has now become the first drugmaker to ...

Explore the exciting world of Eli Lilly (NYSE: LLY) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends ...